KRYS - Krystal Biotech posts updated results from early-stage KB105 study

Krystal Biotech (KRYS) announces updated results from the Phase 1/2 clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis ((ARCI)) associated with mutations in the TGM1 gene.The data showed that repeat doses of KB105 continue to be well tolerated with no adverse events and with no evidence of immune response, systemically or at the sites of application, the company said.The company said that it working on determining the optimal dosing regimen and endpoints to take forward into the next Phase 2 cohort in 2022.Krystal expects the Phase 2 cohort to include pediatric patients.

For further details see:

Krystal Biotech posts updated results from early-stage KB105 study